Which has higher earnings & valuation, SMTI or INMD?

InMode has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $107.48M 2.18 -$37.56M -$3.77 N/A InMode $370.49M 2.35 $93.83M $1.36 11.15

Is SMTI or INMD more profitable?

InMode has a net margin of 23.27% compared to Sanara MedTech's net margin of -31.23%. InMode's return on equity of 13.47% beat Sanara MedTech's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -31.23% -3.19% -0.56% InMode 23.27% 13.47% 11.95%

Which has stronger valuation and earnings, SIBN or SMTI?

SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $206.22M 3.57 -$18.90M -$0.39 N/A Sanara MedTech $107.48M 2.18 -$37.56M -$3.77 N/A

Is SIBN or SMTI more profitable?

SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Sanara MedTech -31.23% -3.19% -0.56%

Which has stronger earnings and valuation, CBLL or SMTI?

Sanara MedTech has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 7.20 -$53.41M -$1.63 N/A Sanara MedTech $107.48M 2.18 -$37.56M -$3.77 N/A

Sanara MedTech (SMTI) Competitors

$25.56 +0.06 (+0.24%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$25.62 +0.07 (+0.25%)

As of 07/24/2026 07:34 PM Eastern

Compare

SMTI vs. INMD, AVR, SIBN, BBNX, and CBLL

Should you buy Sanara MedTech stock or one of its competitors? MarketBeat compares Sanara MedTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanara MedTech include InMode (INMD), Anteris Technologies Global (AVR), SiBone (SIBN), Beta Bionics (BBNX), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.

How does Sanara MedTech compare to InMode?

Sanara MedTech (NASDAQ:SMTI) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sanara MedTech has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, InMode has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

Sanara MedTech currently has a consensus price target of $34.00, suggesting a potential upside of 33.02%. InMode has a consensus price target of $16.00, suggesting a potential upside of 5.47%. Given Sanara MedTech's stronger consensus rating and higher probable upside, research analysts plainly believe Sanara MedTech is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, InMode had 4 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for InMode and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.87 beat InMode's score of 0.96 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Overall Sentiment
Sanara MedTech	Very Positive
InMode	Positive

InMode has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$107.48M	2.18	-$37.56M	-$3.77	N/A
InMode	$370.49M	2.35	$93.83M	$1.36	11.15

InMode has a net margin of 23.27% compared to Sanara MedTech's net margin of -31.23%. InMode's return on equity of 13.47% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
InMode	23.27%	13.47%	11.95%

Summary

InMode beats Sanara MedTech on 11 of the 17 factors compared between the two stocks.

How does Sanara MedTech compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Anteris Technologies Global presently has a consensus price target of $16.00, indicating a potential upside of 96.80%. Sanara MedTech has a consensus price target of $34.00, indicating a potential upside of 33.02%. Given Anteris Technologies Global's higher probable upside, research analysts clearly believe Anteris Technologies Global is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Anteris Technologies Global had 4 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Anteris Technologies Global and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.87 beat Anteris Technologies Global's score of 1.49 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
Anteris Technologies Global	Positive
Sanara MedTech	Very Positive

Anteris Technologies Global has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Sanara MedTech has a net margin of -31.23% compared to Anteris Technologies Global's net margin of -5,148.78%. Sanara MedTech's return on equity of -3.19% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Sanara MedTech has higher revenue and earnings than Anteris Technologies Global. Sanara MedTech is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	414.33	-$94.14M	-$2.23	N/A
Sanara MedTech	$107.48M	2.18	-$37.56M	-$3.77	N/A

8.1% of Sanara MedTech shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Sanara MedTech beats Anteris Technologies Global on 9 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to SiBone?

SiBone (NASDAQ:SIBN) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, SiBone had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for SiBone and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.87 beat SiBone's score of 0.94 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
SiBone	Positive
Sanara MedTech	Very Positive

98.1% of SiBone shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Sanara MedTech	-31.23%	-3.19%	-0.56%

SiBone currently has a consensus target price of $23.50, suggesting a potential upside of 41.40%. Sanara MedTech has a consensus target price of $34.00, suggesting a potential upside of 33.02%. Given SiBone's stronger consensus rating and higher probable upside, analysts plainly believe SiBone is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

SiBone has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.57	-$18.90M	-$0.39	N/A
Sanara MedTech	$107.48M	2.18	-$37.56M	-$3.77	N/A

Summary

SiBone beats Sanara MedTech on 10 of the 17 factors compared between the two stocks.

How does Sanara MedTech compare to Beta Bionics?

Sanara MedTech (NASDAQ:SMTI) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Sanara MedTech has a net margin of -31.23% compared to Beta Bionics' net margin of -60.27%. Sanara MedTech's return on equity of -3.19% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Beta Bionics	-60.27%	-23.00%	-20.55%

Sanara MedTech has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market.

Sanara MedTech has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$107.48M	2.18	-$37.56M	-$3.77	N/A
Beta Bionics	$110.24M	6.41	-$73.20M	-$1.51	N/A

Sanara MedTech currently has a consensus price target of $34.00, suggesting a potential upside of 33.02%. Beta Bionics has a consensus price target of $20.30, suggesting a potential upside of 28.08%. Given Sanara MedTech's higher probable upside, equities research analysts clearly believe Sanara MedTech is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

8.1% of Sanara MedTech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Beta Bionics had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for Beta Bionics and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.87 beat Beta Bionics' score of 1.80 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Overall Sentiment
Sanara MedTech	Very Positive
Beta Bionics	Very Positive

Summary

Sanara MedTech beats Beta Bionics on 9 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Sanara MedTech has a net margin of -31.23% compared to CeriBell's net margin of -63.51%. Sanara MedTech's return on equity of -3.19% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Sanara MedTech	-31.23%	-3.19%	-0.56%

CeriBell currently has a consensus target price of $22.20, suggesting a potential upside of 31.28%. Sanara MedTech has a consensus target price of $34.00, suggesting a potential upside of 33.02%. Given Sanara MedTech's higher possible upside, analysts plainly believe Sanara MedTech is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

8.1% of Sanara MedTech shares are held by institutional investors. 20.1% of CeriBell shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sanara MedTech has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.20	-$53.41M	-$1.63	N/A
Sanara MedTech	$107.48M	2.18	-$37.56M	-$3.77	N/A

In the previous week, CeriBell had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for CeriBell and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.87 beat CeriBell's score of 1.19 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
CeriBell	Positive
Sanara MedTech	Very Positive

CeriBell has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Summary

Sanara MedTech beats CeriBell on 11 of the 16 factors compared between the two stocks.

Get Sanara MedTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMTI vs. The Competition

Export

Metric	Sanara MedTech	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$233.68M	$8.68B	$6.88B	$12.26B
Dividend Yield	N/A	2.52%	2.67%	9.79%
P/E Ratio	-6.78	18.51	27.00	23.71
Price / Sales	2.18	7.23	492.22	75.59
Price / Cash	42.89	18.17	50.54	59.64
Price / Book	38.15	3.19	10.28	6.07
Net Income	-$37.56M	$230.22M	$3.60B	$331.84M
7 Day Performance	2.24%	21.69%	-1.25%	-1.53%
1 Month Performance	10.55%	20.21%	-0.35%	-2.46%
1 Year Performance	0.12%	-4.57%	18.41%	13.66%

Sanara MedTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMTI Sanara MedTech	2.127 of 5 stars	$25.56 +0.2%	$34.00 +33.0%	-0.4%	$233.68M	$107.48M	N/A	60	Positive News
INMD InMode	1.3609 of 5 stars	$15.27 +2.3%	$16.00 +4.8%	+4.4%	$877.43M	$370.49M	11.22	480
AVR Anteris Technologies Global	3.1439 of 5 stars	$8.65 -3.4%	$16.00 +85.0%	+147.9%	$840.63M	$1.91M	N/A	138	News Coverage
SIBN SiBone	3.2525 of 5 stars	$17.21 +1.8%	$23.00 +33.6%	-4.3%	$763.71M	$200.93M	N/A	350	Analyst Upgrade
BBNX Beta Bionics	3.2414 of 5 stars	$17.21 +2.1%	$20.30 +18.0%	+9.8%	$763.09M	$100.25M	N/A	294	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMTI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanara MedTech (SMTI) Competitors

SMTI vs. INMD, AVR, SIBN, BBNX, and CBLL

How does Sanara MedTech compare to InMode?

Summary

How does Sanara MedTech compare to Anteris Technologies Global?

Summary

How does Sanara MedTech compare to SiBone?

Summary

How does Sanara MedTech compare to Beta Bionics?

Summary

How does Sanara MedTech compare to CeriBell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanara MedTech (SMTI) Competitors

SMTI vs. INMD, AVR, SIBN, BBNX, and CBLL

How does Sanara MedTech compare to InMode?

Do institutionals & insiders hold more shares of SMTI or INMD?

Which has more risk & volatility, SMTI or INMD?

Do analysts prefer SMTI or INMD?

Does the media refer more to SMTI or INMD?

Which has higher earnings & valuation, SMTI or INMD?

Is SMTI or INMD more profitable?

Summary

How does Sanara MedTech compare to Anteris Technologies Global?

Do analysts prefer AVR or SMTI?

Does the media prefer AVR or SMTI?

Which has more risk and volatility, AVR or SMTI?

Is AVR or SMTI more profitable?

Which has higher valuation and earnings, AVR or SMTI?

Do insiders and institutionals believe in AVR or SMTI?

Summary

How does Sanara MedTech compare to SiBone?

Does the media favor SIBN or SMTI?

Do insiders & institutionals hold more shares of SIBN or SMTI?

Is SIBN or SMTI more profitable?

Do analysts prefer SIBN or SMTI?

Which has more risk & volatility, SIBN or SMTI?

Which has stronger valuation and earnings, SIBN or SMTI?

Summary

How does Sanara MedTech compare to Beta Bionics?

Is SMTI or BBNX more profitable?

Which has more risk & volatility, SMTI or BBNX?

Which has higher earnings and valuation, SMTI or BBNX?

Do analysts recommend SMTI or BBNX?

Do insiders and institutionals hold more shares of SMTI or BBNX?

Does the media refer more to SMTI or BBNX?

Summary

How does Sanara MedTech compare to CeriBell?

Is CBLL or SMTI more profitable?

Do analysts rate CBLL or SMTI?

Do institutionals & insiders believe in CBLL or SMTI?

Which has stronger earnings and valuation, CBLL or SMTI?

Does the media prefer CBLL or SMTI?

Which has more volatility and risk, CBLL or SMTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools